Want to see TSE:ARCH full AI Analyst Report?
Top Page
Arch Biopartners
(ARCH)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.91
▲(4.71% Upside)
Action:Reiterated
Date:06/24/26
The score is held down primarily by weak financial performance (no current revenue, ongoing losses, cash burn, and negative equity). Technicals provide some support due to a strong uptrend and positive MACD, but very overbought momentum increases downside risk. Valuation remains unattractive because the company is unprofitable (negative P/E) and lacks a dividend.
Positive Factors
Platform-based antibody discovery
Owning a discovery platform and monoclonal antibody pipeline creates a durable competitive advantage: it supports multiple program candidates, enables licensing or co-development deals, and concentrates R&D know‑how. This reduces single‑asset binary risk and improves long-term partner interest and deal optionality.
Negative Factors
No current revenue
Zero revenue is structural for a clinical-stage biotech until approvals or licensing monetization; it forces reliance on external capital or milestone-bearing partnerships. This limits self-funding, increases dilution risk, and makes long-term program advancement contingent on successful financing or partner deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform-based antibody discovery
Owning a discovery platform and monoclonal antibody pipeline creates a durable competitive advantage: it supports multiple program candidates, enables licensing or co-development deals, and concentrates R&D know‑how. This reduces single‑asset binary risk and improves long-term partner interest and deal optionality.
Read all positive factors
Arch Biopartners (ARCH) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$79.48M
Dividend YieldN/A
Average Volume (3M)43.97K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue GrowthN/A
EPS Growth16.99%
CountryCA
Employees6
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding67,933,290
10 Day Avg. Volume31,059
30 Day Avg. Volume43,967
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)-21.63
Price to Sales (P/S)0.00
P/FCF Ratio-53.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)N/A
Arch Biopartners Business Overview & Revenue Model
Company Description
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to addr...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Arch Biopartners’ ability to generate recurring product sales is typically limited until a drug is approved and commercialized; specific, current revenue details for ARCH are null. In general, compani...
Arch Biopartners Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 2.12M | 1.98M | 964.68K | 3.89M |
| Gross Profit | 43.34K | 0.00 | -1.66M | -129.00K | -503.00K | -150.00K |
| EBITDA | -2.33M | -1.29M | -3.53M | -336.00K | -101.00K | -77.02K |
| Net Income | -2.59M | -1.55M | -3.92M | -3.33M | -1.41M | -1.17M |
Balance Sheet | ||||||
| Total Assets | 463.16K | 104.53K | 935.62K | 1.17M | 621.64K | 2.67M |
| Cash, Cash Equivalents and Short-Term Investments | 436.76K | 2.10K | 2.97K | 831.27K | 506.35K | 448.24K |
| Total Debt | 2.73M | 2.84M | 2.77M | 5.02M | 4.41M | 5.16M |
| Total Liabilities | 4.11M | 3.99M | 5.28M | 6.68M | 5.09M | 6.55M |
| Stockholders Equity | -3.64M | -3.88M | -4.35M | -5.51M | -4.47M | -3.88M |
Cash Flow | ||||||
| Free Cash Flow | -1.09M | -1.58M | -2.33M | -234.08K | -1.08M | -2.98M |
| Operating Cash Flow | -1.09M | -1.58M | -2.33M | -234.07K | -1.08M | -2.98M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 1.52M | 1.58M | 1.50M | 559.00K | -421.37K | 2.78M |
Arch Biopartners Technical Analysis
Positive
0.87
Price Trends
0.77
Positive
0.63
Positive
0.85
Positive
Market Momentum
0.07
Negative
66.96
Neutral
92.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Positive. The current price of 0.87 is below the 20-day moving average (MA) of 0.90, above the 50-day MA of 0.77, and above the 200-day MA of 0.85, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 66.96 is Neutral, neither overbought nor oversold. The STOCH value of 92.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ARCH.
Arch Biopartners Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | C$288.51M | -1.75 | -51.42% | ― | ― | 6.61% | |
50 Neutral | C$41.06M | -0.28 | -147.92% | ― | ― | 85.31% | |
46 Neutral | C$79.48M | -27.81 | 70.15% | ― | ― | 16.99% | |
41 Neutral | C$30.66M | -1.81 | -219.30% | ― | ― | -42.77% |
* General Sector Average
TSE:ARCH
Arch Biopartners
1.10
-0.63
-36.42%
TSE:MSCL
Satellos Bioscience
13.81
7.21
109.24%
TSE:MDNA
Medicenna Therapeutics Corp
0.41
-0.60
-59.50%
TSE:BCT
BriaCell Therapeutics
4.74
-5.16
-52.12%
TSE:METX
ME Therapeutics Holdings, Inc.
2.50
-1.50
-37.50%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.